doi: 10.1016/j.semcancer.2017.10.007 41 ElbereI.KalninaI.SilamikelisI.KonradeI.ZaharenkoL.SekaceK.et al
Tirzepatide appeared on the FDA drug shortage list beginning in late 2022
It is not intended to provide medical advice, diagnosis, or treatment
Rodbard, Julio Rosenstock, Luis H
We will further look into this and explore how we can help patients with addiction, potentially with GLP-1, Lange said, also adding that it has to be addressed in a scientific, and obviously also from a regulatory perspective, very rigorous way so we can really see the potential impact of GLP-1 in that space. However, in response to questions from Biospace, a Novo spokesperson said that Lange was referring to the already ongoing work studying semaglutide on liver damage and alcohol use in its phase 2 trial, and that the company has no plans to study the drug in broader addiction indications
Weighing risks and benefits of liraglutidethe FDAs review of a new antidiabetic therapy